Abogen Biosciences

Abogen Biosciences is a Suzhou-based biotech company developing mRNA therapeutics and vaccines. It was co-founded by Dr. Ying Bo, who remains its founder-CEO as of late 2024 . The company gained prominence in November 2021 when it closed a $300 million Series C+ round co-led by SoftBank Vision Fund and existing shareholder 5Y Capital . Its early pipeline centered on infectious disease vaccines, including ARCoV, a COVID-19 mRNA vaccine developed with the Academy of Military Medical Sciences and Walvax Biotechnology, which received emergency use authorization in Indonesia in September 2022 . More recently, Abogen has pivoted toward oncology: in May 2025, its novel mRNA therapeutic tumor vaccine targeting multiple KRAS mutations became the first domestically developed multi-KRAS mRNA cancer vaccine to receive FDA IND approval . The company also established the Ruijin-Abogen Nucleic Acid Drug Research Institute with Shanghai's Ruijin Hospital in November 2024 to accelerate clinical translation . 5Y Capital has remained a consistent backer across multiple rounds .